Dec. 4 at 9:24 PM
$SLS as an FYI while we are waiting for Imminently DUE GPS Registrational Phase 3 Results...
We will be Seeing Some data for SLS009 on Monday
009 is in the Same Class as Several Well Known Blockbusters
SLS009 - Tambiciclib CDKinase Inhibitor
$PFE Pfizers' IBRANCE - Palbociclib CDKinase Inhibitor
Novartis' KISQALI -Ribociclib CDKinase Inhibitor
Eli Lilly's VERZENIO - Abemaciclib CDKinase Inhibitor
and Don't Forget REGOR's Phase 1 CDKinase Asset was bought for
$850M in Cash +
$4B More in Milestones.
Just the Secondary SLS Asset is worth 10 -20x the current Market Cap.